Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction

Natalia López-Andrés, Amélie Rousseau, Riaz Akhtar, Laurent Calvier, Carmen Iñigo, Carlos Labat, Xuegen Zhao, Kennedy Cruickshank, Javier Díez, Faiez Zannad, Patrick Lacolley, Patrick Rossignol

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Cardiotrophin 1 (CT-1), a cytokine belonging to the interleukin 6 family, is increased in hypertension and in heart failure. We aimed to study the precise role of CT-1 on cardiac, vascular, and renal function; morphology; and remodeling in early stages without hypertension. CT-1 (20 μg/kg per day) or vehicle was administrated to Wistar rats for 6 weeks. Cardiac and vascular functions were analyzed in vivo using M-mode echocardiography, Doppler, and echo tracking device and ex vivo using a scanning acoustic microscopy method. Cardiovascular and renal histomorphology were measured by immunohistochemistry, RT-PCR, and Western blot. Kidney functional properties were assessed by serum creatinine and neutrophile gelatinase-Associated lipocalin and microalbuminuria/creatininuria ratio. Without alterations in blood pressure levels, CT-1 treatment increased left ventricular volumes, reduced fractional shortening and ejection fraction, and induced myocardial dilatation and myocardial fibrosis. In the carotid artery of CT-1-treated rats, the circumferential wall stress-incremental elastic modulus curve was shifted leftward, and the acoustic speed of sound in the aorta was augmented, indicating increased arterial stiffness. Vascular media thickness, collagen, and fibronectin content were increased by CT-1 treatment. CT-1-treated rats presented unaltered serum creatinine concentrations but increased urinary and serum neutrophile gelatinase-Associated lipocalin and microalbuminuria/ creatininuria ratio. This paralleled a glomerular and tubulointerstitial fibrosis accompanied by renal epithelial-mesenchymal transition. CT-1 is a new potent fibrotic agent in heart, vessels, and kidney able to induce cardiovascular-renal dysfunction independent from blood pressure. Thus, CT-1 could be a new target simultaneously integrating alterations of heart, vessels, and kidney in early stages of heart failure.

Original languageEnglish (US)
Pages (from-to)563-573
Number of pages11
JournalHypertension
Volume60
Issue number2
DOIs
StatePublished - Aug 1 2012
Externally publishedYes

Fingerprint

Blood Vessels
Fibrosis
Kidney
Creatinine
Heart Failure
Serum
Acoustic Microscopy
Blood Pressure
Hypertension
Tunica Media
cardiotrophin 1
Vascular Stiffness
Epithelial-Mesenchymal Transition
Elastic Modulus
Carotid Arteries
Fibronectins
Acoustics
Echocardiography
Aorta
Wistar Rats

Keywords

  • arterial stiffness
  • cardiotrophin 1
  • fibrosis
  • renal dysfunction
  • ventricular function

ASJC Scopus subject areas

  • Internal Medicine

Cite this

López-Andrés, N., Rousseau, A., Akhtar, R., Calvier, L., Iñigo, C., Labat, C., ... Rossignol, P. (2012). Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension, 60(2), 563-573. https://doi.org/10.1161/HYPERTENSIONAHA.112.194407

Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. / López-Andrés, Natalia; Rousseau, Amélie; Akhtar, Riaz; Calvier, Laurent; Iñigo, Carmen; Labat, Carlos; Zhao, Xuegen; Cruickshank, Kennedy; Díez, Javier; Zannad, Faiez; Lacolley, Patrick; Rossignol, Patrick.

In: Hypertension, Vol. 60, No. 2, 01.08.2012, p. 563-573.

Research output: Contribution to journalArticle

López-Andrés, N, Rousseau, A, Akhtar, R, Calvier, L, Iñigo, C, Labat, C, Zhao, X, Cruickshank, K, Díez, J, Zannad, F, Lacolley, P & Rossignol, P 2012, 'Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction', Hypertension, vol. 60, no. 2, pp. 563-573. https://doi.org/10.1161/HYPERTENSIONAHA.112.194407
López-Andrés, Natalia ; Rousseau, Amélie ; Akhtar, Riaz ; Calvier, Laurent ; Iñigo, Carmen ; Labat, Carlos ; Zhao, Xuegen ; Cruickshank, Kennedy ; Díez, Javier ; Zannad, Faiez ; Lacolley, Patrick ; Rossignol, Patrick. / Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. In: Hypertension. 2012 ; Vol. 60, No. 2. pp. 563-573.
@article{75877a89c8f0426b950943c4e4b34640,
title = "Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction",
abstract = "Cardiotrophin 1 (CT-1), a cytokine belonging to the interleukin 6 family, is increased in hypertension and in heart failure. We aimed to study the precise role of CT-1 on cardiac, vascular, and renal function; morphology; and remodeling in early stages without hypertension. CT-1 (20 μg/kg per day) or vehicle was administrated to Wistar rats for 6 weeks. Cardiac and vascular functions were analyzed in vivo using M-mode echocardiography, Doppler, and echo tracking device and ex vivo using a scanning acoustic microscopy method. Cardiovascular and renal histomorphology were measured by immunohistochemistry, RT-PCR, and Western blot. Kidney functional properties were assessed by serum creatinine and neutrophile gelatinase-Associated lipocalin and microalbuminuria/creatininuria ratio. Without alterations in blood pressure levels, CT-1 treatment increased left ventricular volumes, reduced fractional shortening and ejection fraction, and induced myocardial dilatation and myocardial fibrosis. In the carotid artery of CT-1-treated rats, the circumferential wall stress-incremental elastic modulus curve was shifted leftward, and the acoustic speed of sound in the aorta was augmented, indicating increased arterial stiffness. Vascular media thickness, collagen, and fibronectin content were increased by CT-1 treatment. CT-1-treated rats presented unaltered serum creatinine concentrations but increased urinary and serum neutrophile gelatinase-Associated lipocalin and microalbuminuria/ creatininuria ratio. This paralleled a glomerular and tubulointerstitial fibrosis accompanied by renal epithelial-mesenchymal transition. CT-1 is a new potent fibrotic agent in heart, vessels, and kidney able to induce cardiovascular-renal dysfunction independent from blood pressure. Thus, CT-1 could be a new target simultaneously integrating alterations of heart, vessels, and kidney in early stages of heart failure.",
keywords = "arterial stiffness, cardiotrophin 1, fibrosis, renal dysfunction, ventricular function",
author = "Natalia L{\'o}pez-Andr{\'e}s and Am{\'e}lie Rousseau and Riaz Akhtar and Laurent Calvier and Carmen I{\~n}igo and Carlos Labat and Xuegen Zhao and Kennedy Cruickshank and Javier D{\'i}ez and Faiez Zannad and Patrick Lacolley and Patrick Rossignol",
year = "2012",
month = "8",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.112.194407",
language = "English (US)",
volume = "60",
pages = "563--573",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction

AU - López-Andrés, Natalia

AU - Rousseau, Amélie

AU - Akhtar, Riaz

AU - Calvier, Laurent

AU - Iñigo, Carmen

AU - Labat, Carlos

AU - Zhao, Xuegen

AU - Cruickshank, Kennedy

AU - Díez, Javier

AU - Zannad, Faiez

AU - Lacolley, Patrick

AU - Rossignol, Patrick

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Cardiotrophin 1 (CT-1), a cytokine belonging to the interleukin 6 family, is increased in hypertension and in heart failure. We aimed to study the precise role of CT-1 on cardiac, vascular, and renal function; morphology; and remodeling in early stages without hypertension. CT-1 (20 μg/kg per day) or vehicle was administrated to Wistar rats for 6 weeks. Cardiac and vascular functions were analyzed in vivo using M-mode echocardiography, Doppler, and echo tracking device and ex vivo using a scanning acoustic microscopy method. Cardiovascular and renal histomorphology were measured by immunohistochemistry, RT-PCR, and Western blot. Kidney functional properties were assessed by serum creatinine and neutrophile gelatinase-Associated lipocalin and microalbuminuria/creatininuria ratio. Without alterations in blood pressure levels, CT-1 treatment increased left ventricular volumes, reduced fractional shortening and ejection fraction, and induced myocardial dilatation and myocardial fibrosis. In the carotid artery of CT-1-treated rats, the circumferential wall stress-incremental elastic modulus curve was shifted leftward, and the acoustic speed of sound in the aorta was augmented, indicating increased arterial stiffness. Vascular media thickness, collagen, and fibronectin content were increased by CT-1 treatment. CT-1-treated rats presented unaltered serum creatinine concentrations but increased urinary and serum neutrophile gelatinase-Associated lipocalin and microalbuminuria/ creatininuria ratio. This paralleled a glomerular and tubulointerstitial fibrosis accompanied by renal epithelial-mesenchymal transition. CT-1 is a new potent fibrotic agent in heart, vessels, and kidney able to induce cardiovascular-renal dysfunction independent from blood pressure. Thus, CT-1 could be a new target simultaneously integrating alterations of heart, vessels, and kidney in early stages of heart failure.

AB - Cardiotrophin 1 (CT-1), a cytokine belonging to the interleukin 6 family, is increased in hypertension and in heart failure. We aimed to study the precise role of CT-1 on cardiac, vascular, and renal function; morphology; and remodeling in early stages without hypertension. CT-1 (20 μg/kg per day) or vehicle was administrated to Wistar rats for 6 weeks. Cardiac and vascular functions were analyzed in vivo using M-mode echocardiography, Doppler, and echo tracking device and ex vivo using a scanning acoustic microscopy method. Cardiovascular and renal histomorphology were measured by immunohistochemistry, RT-PCR, and Western blot. Kidney functional properties were assessed by serum creatinine and neutrophile gelatinase-Associated lipocalin and microalbuminuria/creatininuria ratio. Without alterations in blood pressure levels, CT-1 treatment increased left ventricular volumes, reduced fractional shortening and ejection fraction, and induced myocardial dilatation and myocardial fibrosis. In the carotid artery of CT-1-treated rats, the circumferential wall stress-incremental elastic modulus curve was shifted leftward, and the acoustic speed of sound in the aorta was augmented, indicating increased arterial stiffness. Vascular media thickness, collagen, and fibronectin content were increased by CT-1 treatment. CT-1-treated rats presented unaltered serum creatinine concentrations but increased urinary and serum neutrophile gelatinase-Associated lipocalin and microalbuminuria/ creatininuria ratio. This paralleled a glomerular and tubulointerstitial fibrosis accompanied by renal epithelial-mesenchymal transition. CT-1 is a new potent fibrotic agent in heart, vessels, and kidney able to induce cardiovascular-renal dysfunction independent from blood pressure. Thus, CT-1 could be a new target simultaneously integrating alterations of heart, vessels, and kidney in early stages of heart failure.

KW - arterial stiffness

KW - cardiotrophin 1

KW - fibrosis

KW - renal dysfunction

KW - ventricular function

UR - http://www.scopus.com/inward/record.url?scp=84864278283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864278283&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.112.194407

DO - 10.1161/HYPERTENSIONAHA.112.194407

M3 - Article

C2 - 22733458

AN - SCOPUS:84864278283

VL - 60

SP - 563

EP - 573

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -